Technical Analysis for VTGN - VistaGen Therapeutics, Inc.

Grade Last Price % Change Price Change
D 2.08 0.00% 0.00
VTGN closed unchanged on Tuesday, April 13, 2021, on 36 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical VTGN trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Bollinger Band Squeeze Range Contraction -3.70%
Bollinger Band Squeeze Range Contraction -5.02%
BB Squeeze Started Range Contraction -5.02%
20 DMA Resistance Bearish -0.48%
50 DMA Resistance Bearish -0.48%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.48%
BB Squeeze Ended Range Expansion -0.48%
Older End-of-Day Signals for VTGN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% about 17 hours ago
Down 3% about 23 hours ago
Down 2 % about 23 hours ago
Down 1% about 23 hours ago
Fell Below Previous Day's Low about 23 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


VistaGen Therapeutics, Inc. Description

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary new chemical entities (NCEs) for internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and liver cells derived from hPSC technology. The company is also involved in the development of CardioSafe 3D, an in vitro bioassay system for predicting potential cardiotoxicity of new chemical entities (NCEs), including drug rescue NCEs; and LiverSafe 3D, a bioassay system to predict potential liver toxicity of new drug candidates, including potential drug metabolism issues and adverse drug-drug interactions. It has strategic collaborations with University Health Network for hPSC technology research and development; Synterys, Inc. to design, produce, and analyze drug rescue NCEs; and Cato Research, Ltd. for regulatory expertise and clinical development support. The company also has cooperative research and development agreement with the U.S. National Institute of Mental Health for the Phase II clinical study of AV-101. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pharmaceutical Industry Diseases Clinical Development Health Sciences Drug Discovery Clinical Trial Mental Health Disorders In Vitro Metabolism Regenerative Medicine Major Depressive Disorder Depressive Disorder Pharmaceutical Sciences Clinical Pharmacology Treatment Of Major Depressive Disorder Chemical Entities Antidepressants Cartilage Health Net Nmda Receptor Antagonists Prodrug Drug Metabolism

Is VTGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.18
52 Week Low 0.35
Average Volume 3,324,949
200-Day Moving Average 1.26
50-Day Moving Average 2.21
20-Day Moving Average 2.18
10-Day Moving Average 2.15
Average True Range 0.17
ADX 9.14
+DI 13.33
-DI 17.81
Chandelier Exit (Long, 3 ATRs ) 1.92
Chandelier Exit (Short, 3 ATRs ) 2.50
Upper Bollinger Band 2.36
Lower Bollinger Band 2.00
Percent B (%b) 0.23
BandWidth 16.87
MACD Line -0.03
MACD Signal Line -0.02
MACD Histogram -0.0102
Fundamentals Value
Market Cap 153.92 Million
Num Shares 74 Million
EPS -0.83
Price-to-Earnings (P/E) Ratio -2.51
Price-to-Sales 120.30
Price-to-Book 13.51
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.23
Resistance 3 (R3) 2.22 2.17 2.21
Resistance 2 (R2) 2.17 2.13 2.17 2.20
Resistance 1 (R1) 2.12 2.10 2.13 2.13 2.19
Pivot Point 2.07 2.07 2.07 2.07 2.07
Support 1 (S1) 2.02 2.03 2.03 2.03 1.97
Support 2 (S2) 1.97 2.00 1.97 1.96
Support 3 (S3) 1.92 1.97 1.96
Support 4 (S4) 1.93